dMed Biopharmaceutical Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
dMed Biopharmaceutical Co., Ltd. - overview
Established
2016
Location
Shanghai, -, China
Primary Industry
Pharmaceuticals
About
Founded in 2016 and based in Shanghai, China, dMed Biopharmaceutical Co. , Ltd. operates as a clinical contract research organization that provides drug services and solutions to improve and accelerate clinical and drug development. It has branch offices in New York and Eschborn.
The chairman of the board, Lingshi Tan, graduated from University of Pittsburgh and is a chairman of the Drug Information Association Board of Directors. The company has cooperated with ClinsChain, Eurofins, KingMed Diagnostics and other enteprises. In October, it changed its name from dMed to Caidya. In January 2025, Caidya raised USD 165 million in strategic investment from new investor Rubicon Founders.
The company mainly provides new drug R&D contract outsourcing services, providing users with clinical trial design, data management and system development, clinical development and registration strategy services. The company's services can be used in oncology, hematology, rare diseases, pediatric diseases and other disciplines. The company generates revenue by providing new drug R&D contract outsourcing services including early clinical development, clinical trial operations, data management, and drug safety.
Current Investors
Qiming Venture Partners, ZAI Lab Limited, Tigermed
Primary Industry
Pharmaceuticals
Sub Industries
Consulting Services, Pharmaceutical Research & Development
Website
www.caidya.cn
Verticals
HealthTech
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.